Halozyme Therapeutics Inc. Common Stock vs Virtu Financial Inc. Class A Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B), while Virtu Financial Inc. Class A Common Stock trades at $57.56 (market cap $5.19B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.4× Virtu Financial Inc. Class A Common Stock's market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.63% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Virtu Financial Inc. Class A Common Stock for 0 Days on average.
| HALO | VIRT | |
|---|---|---|
Market Cap | $12.58B | $5.19B |
Volume | 2,179,278 | 1,186,043 |
Sector | Health | Financials |
52-Week High | $115.22 | $67.93 |
52-Week Low | $61.63 | $32.53 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.49B | $14.90B |
Dividend Yield | — | 1.63% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →